Aidijia Exenatide Injection

1. Indications and Usage
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is typically recommended for patients who have not achieved adequate glycemic control with metformin, sulfonylureas, or their combination.
2. Dosage and Administration
Initial Dose: The recommended starting dose is 5 mcg administered subcutaneously twice daily.
Administration Schedule: Injections should be given within 60 minutes before the morning and evening meals (or the two main meals of the day). Injections should not be administered after meals.
Dose Titration: Based on clinical response, the dose may be increased to 10 mcg twice daily after at least one month of therapy.
Injection Site: Subcutaneous injections can be administered into the thigh, abdomen, or the area of the upper arm.
3. Mechanism of Action
GLP-1 Receptor Agonism: Exenatide is a GLP-1 receptor agonist that mimics the action of the endogenous incretin hormone GLP-1.
Glucose-Dependent Insulin Secretion: It stimulates glucose-dependent insulin secretion from pancreatic beta cells, meaning it promotes insulin release only when blood glucose levels are elevated.
Suppression of Glucagon: It suppresses inappropriate glucagon secretion, reducing hepatic glucose production.
Glycemic Regulation: It slows gastric emptying and increases satiety, which helps reduce postprandial glucose excursions and body weight.
4. Safety and Warnings
Pancreatic and Thyroid Risks: There have been reports of acute pancreatitis and thyroid C-cell tumors with GLP-1 receptor agonists. The drug should be discontinued if pancreatitis is suspected.
Hypoglycemia: While the risk of hypoglycemia is low when used as monotherapy, the risk increases significantly when combined with sulfonylureas.
Renal Impairment: Acute renal failure and worsening of chronic renal failure have been reported, primarily in patients who experienced severe nausea, vomiting, and diarrhea leading to dehydration.
Gastrointestinal Adverse Reactions: The most common adverse reactions are gastrointestinal in nature.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include nausea, diarrhea, vomiting, dyspepsia, and injection site reactions. Hypoglycemia is common when used with sulfonylureas.
Clinical Research: Clinical trials have demonstrated that exenatide significantly reduces fasting plasma glucose and postprandial glucose, lowers HbA1c, and promotes weight loss in patients with type 2 diabetes.
6. Drug Interations
Oral Medications: Due to the slowing of gastric emptying, exenatide may decrease the absorption and rate of orally administered drugs. Drugs requiring rapid absorption (e.g., certain antibiotics) should ideally be taken at least one hour before exenatide injection.
Digoxin: Co-administration may decrease the peak concentration and delay the time to peak concentration of digoxin.
Sulfonylureas: The risk of hypoglycemia is increased. A dose reduction of the sulfonylurea may be necessary when initiating exenatide.
Warfarin: Changes in INR have been reported when warfarin is used concomitantly with exenatide.
7. Pharmaceutical Information
Composition: The active ingredient is exenatide.
Appearance: The solution is clear and colorless.
Storage: Store in a refrigerator at 2°C to 8°C. Do not freeze. Protect from light.